Growth Metrics

Silence Therapeutics (SLN) Net Cash Flow (2020 - 2025)

Silence Therapeutics' Net Cash Flow history spans 6 years, with the latest figure at -$70.6 million for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 283.22% to -$70.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$110.2 million, a 308.24% decrease, with the full-year FY2025 number at -$110.2 million, down 310.07% from a year prior.
  • Net Cash Flow hit -$70.6 million in Q4 2025 for Silence Therapeutics, down from $40.4 million in the prior quarter.
  • Over the last five years, Net Cash Flow for SLN hit a ceiling of $74.0 million in Q1 2024 and a floor of -$70.6 million in Q4 2025.
  • Historically, Net Cash Flow has averaged -$1.0 million across 5 years, with a median of -$3.6 million in 2021.
  • The widest YoY moves for Net Cash Flow: up 16706.5% in 2022, down 1097.34% in 2022.
  • Tracing SLN's Net Cash Flow over 5 years: stood at -$2.9 million in 2021, then plummeted by 1097.34% to -$34.9 million in 2022, then surged by 94.44% to -$1.9 million in 2023, then skyrocketed by 2085.72% to $38.5 million in 2024, then tumbled by 283.22% to -$70.6 million in 2025.
  • Business Quant data shows Net Cash Flow for SLN at -$70.6 million in Q4 2025, $40.4 million in Q3 2025, and -$23.4 million in Q2 2025.